32967721|t|Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer's disease.
32967721|a|BACKGROUND: We aimed to investigate the clinical correlates of principal components (PCs) of tau positron emission tomography (PET) and their predictability for longitudinal changes in tau accumulation in Alzheimer's disease (AD). METHODS: We enrolled 272 participants who underwent two PET scans [18F-flortaucipir for tau and 18F-florbetaben for amyloid-beta (Abeta)], brain magnetic resonance imaging, and neuropsychological tests as baseline assessments. Among them, 187 participants underwent the same follow-up assessments after an average of 2 years. Using Abeta-positive AD dementia-specific PCs obtained from the baseline scans of 56 Abeta-positive patients with AD dementia, we determined the expression of the first two PCs (PC1 and PC2) in all participants. We assessed the correlation of PC expression with baseline clinical characteristics and tau accumulation rates. Moreover, we investigated the predictability of PCs for the longitudinal tau accumulation in training and test sets. RESULTS: PC1 corresponded to the tau distribution pattern in AD, while the two PC2 extremes reflected the parietal or temporal predominance of tau distribution. PC1 expression increased with tau burden and decreased with cognitive impairment, while PC2 expression decreased with advanced age and visuospatial and attention function deterioration. The tau accumulation rate was positively correlated with PC1 expression (greater tau burden) and negatively correlated with PC2 expression (temporal predominance). A regression model using both PCs could predict longitudinal changes in the tau burden (intraclass correlation coefficient = 0.775, R2 = 0.456 in test set). CONCLUSIONS: PC analysis of tau PET could be useful for evaluating disease progression, characterizing the tau distribution pattern, and predicting longitudinal tau accumulation.
32967721	24	27	tau	Gene	4137
32967721	74	77	tau	Gene	4137
32967721	94	113	Alzheimer's disease	Disease	MESH:D000544
32967721	208	211	tau	Gene	4137
32967721	300	303	tau	Gene	4137
32967721	320	339	Alzheimer's disease	Disease	MESH:D000544
32967721	341	343	AD	Disease	MESH:D000544
32967721	413	429	18F-flortaucipir	Chemical	MESH:C000591008
32967721	434	437	tau	Gene	4137
32967721	442	457	18F-florbetaben	Chemical	MESH:C527756
32967721	462	474	amyloid-beta	Gene	351
32967721	476	481	Abeta	Gene	351
32967721	678	683	Abeta	Gene	351
32967721	693	704	AD dementia	Disease	MESH:D000544
32967721	757	762	Abeta	Gene	351
32967721	772	780	patients	Species	9606
32967721	786	797	AD dementia	Disease	MESH:D000544
32967721	850	853	PC1	Gene	5122
32967721	858	861	PC2	Gene	5311
32967721	915	917	PC	Gene	5091
32967721	972	975	tau	Gene	4137
32967721	1069	1072	tau	Gene	4137
32967721	1122	1125	PC1	Gene	5122
32967721	1146	1149	tau	Gene	4137
32967721	1174	1176	AD	Disease	MESH:D000544
32967721	1192	1195	PC2	Gene	5311
32967721	1256	1259	tau	Gene	4137
32967721	1274	1277	PC1	Gene	5122
32967721	1304	1307	tau	Gene	4137
32967721	1334	1354	cognitive impairment	Disease	MESH:D003072
32967721	1362	1365	PC2	Gene	5311
32967721	1422	1458	and attention function deterioration	Disease	MESH:D001289
32967721	1464	1467	tau	Gene	4137
32967721	1517	1520	PC1	Gene	5122
32967721	1541	1544	tau	Gene	4137
32967721	1584	1587	PC2	Gene	5311
32967721	1700	1703	tau	Gene	4137
32967721	1794	1796	PC	Gene	5091
32967721	1809	1812	tau	Gene	4137
32967721	1888	1891	tau	Gene	4137
32967721	1942	1945	tau	Gene	4137
32967721	Association	MESH:C000591008	4137
32967721	Association	4137	5091
32967721	Association	MESH:D001289	5311
32967721	Association	4137	5311
32967721	Positive_Correlation	4137	5122
32967721	Association	MESH:D000544	5122
32967721	Association	MESH:D000544	351
32967721	Association	MESH:D000544	4137
32967721	Association	MESH:D000544	5311
32967721	Association	MESH:C527756	351
32967721	Negative_Correlation	MESH:D003072	5122

